Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Chairperson Perspective: Improving HR+/HER2- Breast Cancer Outcomes with TROP2 Antibody-Drug Conjugates
Description:
Host: Aditya Bardia, MD, MPH
The recent approvals of therapies for hormone-receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) have augmented the treatment armamentarium in this setting, giving clinicians more options for their patients. However, it may be challenging to select the optimal therapy for individual patients. Moreover, it is important to differentiate between the 2 available TROP2-directed antibody-drug conjugates (ADCs). This activity reviews challenges in treating HR+, HER2- MBC, the role of TROP2-directed ADCS, and how to tailor therapy for individual patients.